guest ::
| Home > Publications database > Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective. > print |
| Home > Publications database > Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective. > print |
| 001 | 125391 | ||
| 005 | 20240228145526.0 | ||
| 024 | 7 | _ | |a 10.1038/nrclinonc.2017.59 |2 doi |
| 024 | 7 | _ | |a pmid:28508875 |2 pmid |
| 024 | 7 | _ | |a 1743-4254 |2 ISSN |
| 024 | 7 | _ | |a 1743-4262 |2 ISSN |
| 024 | 7 | _ | |a 1759-4774 |2 ISSN |
| 024 | 7 | _ | |a 1759-4782 |2 ISSN |
| 024 | 7 | _ | |a altmetric:20186026 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-01521 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Moreno, Lucas |b 0 |
| 245 | _ | _ | |a Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective. |
| 260 | _ | _ | |a New York, NY |c 2017 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1660829021_30405 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a In the past decade, the landscape of drug development in oncology has evolved dramatically; however, this paradigm shift remains to be adopted in early phase clinical trial designs for studies of molecularly targeted agents and immunotherapeutic agents in paediatric malignancies. In drug development, prioritization of drugs on the basis of knowledge of tumour biology, molecular 'drivers' of disease and a drug's mechanism of action, and therapeutic unmet needs are key elements; these aspects are relevant to early phase paediatric trials, in which molecular profiling is strongly encouraged. Herein, we describe the strategy of the Innovative Therapies for Children with Cancer (ITCC) Consortium, which advocates for the adoption of trial designs that enable uninterrupted patient recruitment, the extrapolation from studies in adults when possible, and the inclusion of expansion cohorts. If a drug has neither serious dose-related toxicities nor a narrow therapeutic index, then studies should generally be started at the adult recommended phase II dose corrected for body surface area, and act as dose-confirmation studies. The use of adaptive trial designs will enable drugs with promising activity to progress rapidly to randomized studies and, therefore, will substantially accelerate drug development for children and adolescents with cancer. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Antineoplastic Agents |2 NLM Chemicals |
| 700 | 1 | _ | |a Pearson, Andrew D J |b 1 |
| 700 | 1 | _ | |a Paoletti, Xavier |b 2 |
| 700 | 1 | _ | |a Jimenez, Irene |b 3 |
| 700 | 1 | _ | |a Geoerger, Birgit |b 4 |
| 700 | 1 | _ | |a Kearns, Pamela R |b 5 |
| 700 | 1 | _ | |a Zwaan, C Michel |b 6 |
| 700 | 1 | _ | |a Doz, Francois |b 7 |
| 700 | 1 | _ | |a Baruchel, Andre |b 8 |
| 700 | 1 | _ | |a Vormoor, Josef |b 9 |
| 700 | 1 | _ | |a Casanova, Michela |b 10 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 11 |u dkfz |
| 700 | 1 | _ | |a Morland, Bruce |b 12 |
| 700 | 1 | _ | |a Vassal, Gilles |b 13 |
| 700 | 1 | _ | |a Cancer, Innovative Therapies for Children with |b 14 |e Collaboration Author |
| 773 | _ | _ | |a 10.1038/nrclinonc.2017.59 |g Vol. 14, no. 8, p. 497 - 507 |0 PERI:(DE-600)2491414-9 |n 8 |p 497 - 507 |t Nature reviews / Clinical oncology |v 14 |y 2017 |x 1759-4782 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:125391 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT REV CLIN ONCOL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NAT REV CLIN ONCOL : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|